We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 8 for:    ampio

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03182686
First Posted: June 9, 2017
Last Update Posted: October 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ampio Pharmaceuticals. Inc.
  Purpose

This is a phase 3 randomized study is to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.

There will be a 7-day screening period for each subject followed by a 12-week participation period.

The primary trial objective is to evaluate the clinical efficacy of Ampion using the OMERACT-OARSI criteria D and percent change from baseline (using the WOMAC 3.1 Index and PGA as assessments).

The secondary trial objectives are to evaluate the safety of a single intra-articular injection (4 mL) of Ampion.


Condition Intervention Phase
Osteoarthritis, Knee Knee Osteoarthritis Knee Arthritis Knee Pain Chronic Biological: Ampion Other: Saline Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

Resource links provided by NLM:


Further study details as provided by Ampio Pharmaceuticals. Inc.:

Primary Outcome Measures:
  • Evaluate responder status using OMERACT-OARSI scenario D using WOMAC A subscore, WOMAC C subscore, and PGA as composite endpoints; H0:π = 30% versus HA:π > 30% [ Time Frame: Week 12 ]

    A patient in this study will be considered a responder for the purpose of efficacy analysis if the following criteria is met.

    1. The patient has a percent improvement in pain (WOMAC A) of ≥50% and an absolute change in pain from baseline of ≥ 1 point on the 5-point Likert scale or the patient has a percent improvement in function (WOMAC C) ≥50% and an absolute change in function from baseline of ≥1 point on the 5-point Likert scale.

      If the patient does not meet this criterion, then

    2. The patient demonstrates improvement in at least 2 of the following:

      • Improvement in pain (WOMAC A) ≥20% and a 0.5 point absolute change in pain from Baseline on the 5-point Likert scale
      • Improvement in function (WOMAC C) ≥20% and a 0.5 point absolute change in function from Baseline on the 5-point Likert scale
      • Improvement in patient global assessment (PGA) ≥20% and a 0.5 point absolute change in PGA from Baseline on the 5-point Likert scale


Secondary Outcome Measures:
  • Percent Reduction in WOMAC A pain subscore [ Time Frame: Week 12 ]
    Percent change in WOMAC pain subscore (WOMAC A) from Baseline (Day 0) to Week 12 using the WOMAC osteoarthritis Index, 5-point Likert Scale

  • Safety: Incidence and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: Week 12 ]
    Incidence and severity of treatment-emergent adverse events (TEAEs)


Enrollment: 169
Actual Study Start Date: June 19, 2017
Estimated Study Completion Date: December 11, 2017
Estimated Primary Completion Date: December 11, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ampion
Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
Biological: Ampion
Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% HSA)
Saline
Saline, solution, 4 mL, single intra-articular injection
Other: Saline
0.9% sodium chloride

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to provide written informed consent to participate in the study;
  • Willing and able to comply with all study requirements and instructions of the site study staff;
  • Must be ambulatory;
  • Study knee must have a clinical diagnosis of osteoarthritis (OA) supported by radiological evidence (Kellgren Lawrence Grade 4) which is assessed locally (x-rays within the past 6 months of screening are acceptable);
  • Moderate to moderately-severe OA pain in the study knee (rating of at least 1.5 on the WOMAC A, 5-point Likert Pain Subscale);
  • Moderate to moderately-severe OA function in the study knee (rating of at least 1.5 on the WOMAC C, 5-point Likert Function Subscale);
  • WOMAC A, 5-point Likert pain subscale <1.5 in the contralateral knee;
  • Ability to discontinue non-steroidal anti-inflammatory drug (NSAID) use at Screening visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical study (low-dose aspirin (81 mg) is allowed during the study);
  • No analgesia (including acetaminophen) taken 24 hours prior to an efficacy measure;
  • No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.).

Exclusion Criteria:

  • As a result of medical review and screening investigation, the Principal Investigator considers the subject unfit for the study
  • A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)
  • A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)
  • Presence of tense effusions
  • Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator
  • Isolated patella femoral syndrome, also known as chondromalacia
  • Any other disease or condition interfering with the free use and evaluation of the study knee for the duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis)
  • Major injury to the study knee within the 12 months prior to screening
  • Severe hip osteoarthritis ipsilateral to the study knee
  • Any pain that could interfere with the assessment of study knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)
  • Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study
  • Pregnancy or planning to become pregnant during the study
  • Use of the following medications:

    1. No intra-articular (IA) injected medications in the study knee during the study (or 12 weeks prior to Baseline).
    2. No analgesics containing opioids.
    3. NSAIDs are not permitted during the study; acetaminophen is available as a rescue medication during the study from the provided supply.
    4. No topical treatment on the study knee during the study
    5. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as low-dose Aspirin (81 mg) and Plavix are allowed)
    6. No systemic treatments that may interfere with safety or efficacy assessments during the study
    7. No immunosuppressants
    8. No use of systemic or intra-articular corticosteroids
  • No human albumin treatment in the 3 months before randomization or throughout the duration of the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03182686


Locations
United States, Alabama
Central Research Associates, Inc.
Birmingham, Alabama, United States, 35205
United States, California
CORE Orthopaedic Medical Center
Encinitas, California, United States, 92024
St. Joseph Heritage
Fullerton, California, United States, 92835
Artemis Institute for Clinical Research
San Diego, California, United States, 92103
Westlake Medical Research
Thousand Oaks, California, United States, 91360
United States, Georgia
Drug Studies America
Marietta, Georgia, United States, 30060
United States, Illinois
Healthcare Research Netword
Blue Island, Illinois, United States, 60406
United States, Kansas
Heartland Research Associates
Wichita, Kansas, United States, 67207
United States, Maryland
Arthritis Treatment Center
Frederick, Maryland, United States, 21702
United States, Missouri
Healthcare Network Research
Hazelwood, Missouri, United States, 63042
United States, South Carolina
Coastal Carolina Center at Lowcountry Orthopaedics
North Charleston, South Carolina, United States, 29406
United States, Texas
Tekton Research
Austin, Texas, United States, 78745
United States, Washington
Northwest Clinical Research Center
Bellevue, Washington, United States, 98007
Sponsors and Collaborators
Ampio Pharmaceuticals. Inc.
Investigators
Study Director: David Bar-Or, MD Ampio Pharmaceuticals. Inc.
Study Director: Holly Mitzel Ampio Pharmaceuticals. Inc.
  More Information

Responsible Party: Ampio Pharmaceuticals. Inc.
ClinicalTrials.gov Identifier: NCT03182686     History of Changes
Other Study ID Numbers: AP-003-C
First Submitted: June 6, 2017
First Posted: June 9, 2017
Last Update Posted: October 13, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ampio Pharmaceuticals. Inc.:
osteoarthritis
osteoarthritis of the knee
OA
OAK
Kellgren Lawrence (KL)

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases